NCT04248855 - Assessment of KAN-101 in Celiac Disease (ACeD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

October 8, 2021

Conditions

Celiac Disease

Interventions

DRUG

KAN-101

Intravenous (IV) infusion

DRUG

Placebo

Intravenous (IV) infusion

Trial Locations (13)

10032

Celiac Disease Center at Columbia University, New York

21225

Parexel International- EPCU Baltimore, Baltimore

27607

North Carolina Clinical Research, Raleigh

33180

Innovative Medical Research of South Florida, Aventura

33705

GCP Research, St. Petersburg

37421

WR-ClinSearch, LLC, Chattanooga

43213

Aventiv Research, Columbus

49519

West Michigan Clinical Research Center, Wyoming

55905

Mayo Clinic, Rochester

70072

Tandem Clinical Research, Marrero

84088

Advanced Clinical Research, West Jordan

92801

Anaheim Clinical Trials, Anaheim

94598

Diablo Clinical Research, Walnut Creek

All Listed Sponsors

lead

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

INDUSTRY